Geometry.Net - the online learning center
Home  - Health_Conditions - Activated Protein C Resistance

e99.com Bookstore
  
Images 
Newsgroups
Page 5     81-87 of 87    Back | 1  | 2  | 3  | 4  | 5 
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

         Activated Protein C Resistance:     more detail
  1. Activated Protein C Resistance

81. Esterase Stain, Specific
Leiden, R506Q polymorphism. This is associated with activated proteinC resistance and an increased risk for venous thrombosis.
http://www.aruplab.com/guides/clt/tests/clt_a210.htm

ARUP's Guide to Clinical Laboratory Testing (CLT)
A B C D ... Search Note: Test code links throughout this Guide refer to the corresponding test in the User's Guide.
Esterase Stain, Specific
Test Number:
Methodology:

Cytochemical Stain/Microscopic
Clinical Significance:
The esterase enzyme is found exclusively within the primary granules of late myeloblasts, promyelocytes, and more mature myeloid cells that hydrolyze the substrate naphthol AS-D chloroacetate. The specific esterase stain is often used to determine myeloid lineage in the blasts of acute leukemias. Its reactivity parallels that of myeloperoxidase and Sudan Black B, except that, unlike Sudan Black B, there is no reaction in the granules of monocytes. It is used less often than the other two stains for myeloid lineage, however, because it is regarded as less sensitive and less consistent.
See also: Sudan Black B Stain
Reference Interval:
No reference interval
Reference:
Beutler E, et al. Williams hematology , 5th ed. 1995; New York: McGraw-Hill Company, L 70-71.

82. Faculty Directory
Defects in coagulation factor V that result in resistance to activated proteinC (APC) are the most common known genetic risk factor for thrombosis.
http://www.mcis.duke.edu/cgi-bin/fps/getPerson.pl?personid=973

83. APCR And Factor V Leiden Mutation
Edition. LexiComp, Cleveland, 2001; 327-358. activated protein CResistance and the Factor V Leiden Mutation CO004550. Related
http://www.mgh.harvard.edu/labmed/lab/coag/handbook/CO004550.htm

Laboratory Medicine
Laboratories Coagulation Handbook
APCR and Factor V Leiden Mutation
Coag Test Handbook Index
From:
Elizabeth M. Van Cott, M.D., and Michael Laposata, M.D., Ph.D., "Coagulation." In: Jacobs DS et al, ed. The Laboratory Test Handbook , 5th Edition. Lexi-Comp, Cleveland, 2001; 327-358. Activated Protein C Resistance and the Factor V Leiden Mutation [CO004550] Related Information Synonyms Activated Protein C Resistance; APC; Protein C Resistance, Activated
Applies to Factor V Leiden Mutation
Abstract Resistance to activated protein C (APC) is a condition which leads to a hypercoagulable state with an increased risk for venous thrombosis. The effect of exogenous APC on patient's clotting time [usually activated partial thromboplastin time (PTT)] is used to detect presence of resistance to APC (as occurs in individuals with the factor V Leiden mutation). A few laboratories might use clotting times other than the PTT. DNA-based assays can be used to directly detect the presence of the factor V Leiden mutation.
Specimen Plasma (for clotting time-based screening assay) and whole blood (for DNA-based confirmatory assay)

84. The Recurrent Miscarriage Clinic - Research Publications From St Mary's RMC
Second trimester pregnancy loss is associated with activated proteinC resistance. Rai R, Regan L, Hadley E, Dave M, Cohen H. British
http://www.st-marys.org.uk/specialist/miscarriage_clinic/publications.htm
An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases.
Clifford K, Rai RS, Watson H and Regan L.
Human Reproduction 1994; 9 (7): 1328 -1332 Antiphospholipid antibodies and beta 2 glycoprotein-1 in 500 women with recurrent miscarriage: results of a comprehensive screening approach.
Rai RS, Regan L, Clifford K, Pickering W, Dave M, McNally T and Cohen H.
Human Reproduction 1995 ; 10 (8) 2001 -2005. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.
Rai RS, Clifford K, Cohen H and Regan L.
Human Reproduction 1995 ; 10 (12): 3301 -3304. Second trimester pregnancy loss is associated with activated protein C resistance.
Rai R, Regan L, Hadley E, Dave M, Cohen H.
British Journal of Haematology 1995; 92: 489 -450. Association of bacterial vaginosis with a history of second trimester miscarriage.
Llahi-Camp J, Rai R, Ison C, Regan L, Taylor-Robinson D.
Human Reproduction 1996 ;11 (7) 1575 - 1578

85. CBER - Clinical Review Of Recombinant Activated Protein C (rhAPC) XIGRIS
Patients with a known hypercoagulable condition including activated protein Cresistance; a hereditary deficiency of protein C, protein S, or antithrombin
http://www.fda.gov/cber/review/droteli112101r1.htm
Blood Therapeutics Vaccines Allergenics ... About Us
Product Approval Information - Licensing Action
FDA CLINICAL REVIEW
DROTRECOGIN ALFA (ACTIVATED) [RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC)] XIGRIS BLA# 125029/0 Approved: November 21, 2001 U.S. Food and Drug Administration
Clinical Reviewer: LINDA M. FORSYTH, M.D.
Clinical Reviewer: ROBERT LINDBLAD, M.D.
Statistician: JAWAHAR TIWARI, Ph.D.
TABLE OF CONTENTS
Section I - Introduction
    Purpose
    Sponsor
    Product
    Indication
    Background
    Manufacturing
    Pharmacokinetics
    Brief Description of Studies
Section II - Phase II - Clinical Study
    Study Description Study Design Efficacy
Section III - Phase III - Clinical Study
    Study Description Study Design Selection of Study Population Phase 3 Inclusion Criteria Phase 3 Exclusion Criteria Statistical Plan Results of Interim Analyses Removal of Patients from Therapy or Assessment
Section IIIA - Baseline characteristics
    Gender Age Ethnic Origin Disease Severity Pre-infusion SIRS and Organ Failure Status Baseline SOFA Scores Solicited patient history Central laboratory data
Section IIIB - EFFICACY
    Primary Efficacy Analysis: 28 Day All Cause Mortality and Treatment Effect Treatment Effect and Gender Treatment Effect and Ethnic Origin Treatment Effect and Age Class Treatment Effect and Baseline APACHE II Score Treatment Effect in Subgroups Defined by Organ Failure and APACHE II Quartiles Treatment Effect and Shock Treatment Effect and SOFA Scores Treatment Effect and Heparin Use

86. Katalog - Wirtualna Polska
Serwis Katalog w Wirtualna Polska S.A. pierwszy portal w Polsce.
http://katalog.wp.pl/DMOZ/Health/Conditions_and_Diseases/Blood_Disorders/Blood_C
Poczta Czat SMS Pomoc Szukaj.wp.pl: -Katalog -Polskie www -¦wiatowe www -Wirtualna Polska -FTP/Pliki -Grupy dyskusyjne -Encyklopedia -Produkty wp.pl Katalog Katalog ¦wiatowy DMOZ ... Blood Disorders > Blood Coagulation Fakty o Katalogu Pomoc Regulamin Serwis szukaj ... Ostatnio dodane
NAWIGACJA Fakty o katalogu
Pomoc

Regulamin

Serwis Szukaj
...
FAQ

Dodaj stronê
Katalog WP

Polskie Strony WWW

Oferta dla firm

WP-HIT
... Wirtualna Polska

87. Fattore V Leiden - Trombofilia - Associazione Italiana Pazienti Anticoagulati -
Translate this page Resistenza alla proteina C attivata E' una causa frequente di trombofilia.Possono esserci ragioni acquisite o transitorie di resistenza
http://utenti.tripod.it/aipalink/F-Leiden.html
Resistenza alla proteina C attivata
E' una causa frequente di trombofilia. Possono esserci ragioni acquisite o transitorie di resistenza alla proteina C attivata, ma essenzialmente essa è riconducibile ad una condizione ereditaria nota come Fattore V Leiden . Si tratta della mutazione di un gene che codifica per il fattore V della coagulazione, mutazione che causa una risposta insufficiente alla proteina C (un anticoagulante naturale) nella sua forma attiva, e di conseguenza un rischio maggiore di trombosi rispetto alla popolazione generale. Un fattore V mutato è inattivato con maggiore lentezza e resta in circolo più a lungo, producendo a volte alterazione in alcuni indici di coagulazione. Il rischio è molto maggiore per i portatori della mutazione in forma omozigote (presente su entrambi i geni) rispetto a quella eterozigote (un solo gene mutato).
Sebbene questa alterazione sia riscontrata con una certa frequenza nelle persone che hanno avuto episodi trombotici con o senza altre cause concomitanti, buona parte dei portatori di fattore V Leiden resta asintomatico. Resistenza alla proteina C attivata Fattore V Leiden Fattore V Leiden Fattore V Leiden, proteina C attivata

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

Page 5     81-87 of 87    Back | 1  | 2  | 3  | 4  | 5 

free hit counter